Suppr超能文献

实现血管靶向治疗的潜力:联合血管破坏剂和抗血管生成剂治疗癌症的基本原理。

Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.

作者信息

Siemann D W, Chaplin D J, Horsman M R

机构信息

a Department of Radiation Oncology , University of Florida , Gainesville , FL , USA.

b Mateon Therapeutics , South San Francisco , CA , USA.

出版信息

Cancer Invest. 2017 Sep 14;35(8):519-534. doi: 10.1080/07357907.2017.1364745. Epub 2017 Sep 5.

Abstract

Vascular targeted therapies (VTTs) are agents that target tumor vasculature and can be classified into two categories: those that inhibit angiogenesis and those that directly interfere with established tumor vasculature. Although both the anti-angiogenic agents (AAs) and the vascular disrupting agents (VDAs) target tumor vasculature, they differ in their mechanism of action and therapeutic application. Combining these two agents may realize the full potential of VTT and produce an effective therapeutic regimen. Here, we review AAs and VDAs (monotherapy and in combination with conventional therapies). We also discuss the rationale of combined VTT and its potential to treat cancer.

摘要

血管靶向治疗(VTTs)是一类靶向肿瘤血管的药物,可分为两类:抑制血管生成的药物和直接干扰已形成的肿瘤血管的药物。尽管抗血管生成药物(AAs)和血管破坏剂(VDAs)都靶向肿瘤血管,但它们的作用机制和治疗应用有所不同。联合使用这两种药物可能会实现血管靶向治疗的全部潜力,并产生有效的治疗方案。在此,我们综述了抗血管生成药物和血管破坏剂(单药治疗以及与传统疗法联合使用的情况)。我们还讨论了联合血管靶向治疗的基本原理及其治疗癌症的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验